BR0206160A - Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos - Google Patents

Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos

Info

Publication number
BR0206160A
BR0206160A BR0206160-0A BR0206160A BR0206160A BR 0206160 A BR0206160 A BR 0206160A BR 0206160 A BR0206160 A BR 0206160A BR 0206160 A BR0206160 A BR 0206160A
Authority
BR
Brazil
Prior art keywords
treatment
medicines
tnf antibodies
anemic patients
septic
Prior art date
Application number
BR0206160-0A
Other languages
English (en)
Inventor
Leah S Teoh
William T Barchuck
Steven A Fischkoff
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of BR0206160A publication Critical patent/BR0206160A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Abstract

"USO DE ANTICORPOS ANTI-TNF COMO MEDICAMENTOS NO TRATAMENTO DE DISTúRBIOS SéPTICOS DE PACIENTES ANêMICOS". A presente invenção se refere ao tratamento de um paciente anêmico com níveis elevados de IL-6 pela administração de um antagonista de TNF. Também se refere ao tratamento sepse em um paciente pela administração de um antagonista de TNF.
BR0206160-0A 2001-05-25 2002-05-23 Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos BR0206160A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29381801P 2001-05-25 2001-05-25
PCT/US2002/018362 WO2002096461A1 (en) 2001-05-25 2002-05-23 Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients

Publications (1)

Publication Number Publication Date
BR0206160A true BR0206160A (pt) 2004-10-26

Family

ID=23130712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206160-0A BR0206160A (pt) 2001-05-25 2002-05-23 Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos

Country Status (5)

Country Link
US (1) US20030012786A1 (pt)
AR (1) AR034049A1 (pt)
BR (1) BR0206160A (pt)
PE (1) PE20021151A1 (pt)
WO (1) WO2002096461A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ536216A (en) * 1996-02-09 2006-08-31 Abbott Biotech Ltd Use of an isolated antibody D2E7 for the treatment of a disorder in which TNF(alpha) activity is detrimental
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
PT1944322E (pt) * 2002-07-19 2015-07-01 Abbvie Biotechnology Ltd Tratamento de distúrbios relacionados com tnf-alfa
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
WO2005009464A1 (en) * 2003-07-25 2005-02-03 Lopez De Silanes Juan Administration of anti-cytokine f(ab')2 antibody fragments
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
NZ627177A (en) * 2005-05-16 2016-02-26 Abbvie Biotechnology Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
BRPI0618085A2 (pt) 2005-11-01 2011-08-16 Abbott Biotech Ltd processos e kits para diagnóstico de espondilite ancilosante usando biomarcadores
NZ596517A (en) 2006-04-05 2013-06-28 Abbott Biotech Ltd Antibody purification
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
AU2007269791B2 (en) * 2006-06-30 2013-10-03 Abbvie Biotechnology Ltd Automatic injection device
CA2667655A1 (en) 2006-10-27 2008-05-15 Abbott Biotechnology Ltd. Crystalline anti-htnfalpha antibodies
EP2679996A1 (en) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
US8999337B2 (en) * 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
EP2173380A4 (en) * 2007-07-13 2011-08-31 Abbott Biotech Ltd METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER
MX2010001488A (es) 2007-08-08 2010-03-01 Abbott Lab Composiciones y metodos para cristalizar anticuerpos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
MX354100B (es) 2007-11-30 2018-02-13 Abbvie Biotechnology Ltd Star Formulaciones de proteinas y metodos para elaborarlas.
WO2009086550A1 (en) * 2008-01-03 2009-07-09 Abbott Laboratories Predicting long-term efficacy of a compound in the treatment of psoriasis
CA2711984A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
MX2011011541A (es) * 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
CN104490767A (zh) * 2009-05-04 2015-04-08 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
NZ627052A (en) * 2009-12-15 2015-12-24 Abbvie Biotechnology Ltd Improved firing button for automatic injection device
PT2575884T (pt) 2010-06-03 2018-10-31 Abbvie Biotechnology Ltd Utilizações e composições para o tratamento de hidradenite supurativa (hs)
KR101841527B1 (ko) 2010-11-11 2018-03-23 애브비 바이오테크놀로지 리미티드 개선된 고농도 항－ＴＮＦα 항체 액체 제형
WO2012103141A1 (en) 2011-01-24 2012-08-02 Abbott Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

Also Published As

Publication number Publication date
PE20021151A1 (es) 2002-12-18
US20030012786A1 (en) 2003-01-16
AR034049A1 (es) 2004-01-21
WO2002096461A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
BR0206160A (pt) Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
ATE510580T1 (de) Modulares stimulationsleitungsnetz
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
DK1750716T3 (da) Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HK1061661A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0114389A (pt) Terapia antitumor que inclui derivado de distamicina
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
CY1111900T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda)
SE9902597D0 (sv) New use
GEP201606538B (en) Preoperative treatment of post operative pain
EA200601514A1 (ru) Производные пиперазинмочевины для лечения эндометриоза
SG165152A1 (en) Chemokine receptor antagonists and methods of use thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]